As
filed with the Securities and Exchange Commission on September 19, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
SONNET
BIOTHERAPEUTICS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
2834 |
|
20-2932652 |
(State
or other jurisdiction of
incorporation or organization) |
|
(Primary
Standard Industrial
Classification
Code Number) |
|
(I.R.S
Employer
Identification
Number) |
100
Overlook Center, Suite 102
Princeton,
New Jersey 08540
Telephone:
609-375-2227
(Address,
including zip code, and telephone number,
including
area code, of registrant’s principal executive offices)
Pankaj
Mohan, Ph.D.
CEO
and Chairman
Sonnet
BioTherapeutics Holdings, Inc.
100
Overlook Center, Suite 102
Princeton,
New Jersey 08540
Telephone:
(609) 375-2227
(Name,
address, including zip code, and telephone number,
including
area code, of agent for service)
Please send copies of all communications to:
Steven
M. Skolnick, Esq.
Alexander
E. Dinur, Esq.
Lowenstein Sandler LLP
1251 Avenue of the Americas
New York, NY 10020
Telephone: (212) 262-6700 |
|
Joseph
Lucosky, Esq.
Lucosky
Brookman LLP
101
Wood Avenue South, 5th Floor
Woodbridge,
NJ 08830
Telephone:
(732) 395-4400 |
Approximate
date of commencement of proposed sale to the public:
As
soon as practicable after the effective date of this registration statement.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box: ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ |
Accelerated
filer ☐
|
Non-accelerated
filer ☒ |
Smaller
reporting company ☒
|
|
Emerging
growth company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED SEPTEMBER 19, 2023
PRELIMINARY
PROSPECTUS
Up
to Shares of Common Stock
Pre-Funded
Warrants to Purchase up to Shares of Common Stock
Common
Warrants to Purchase up to Shares of Common Stock
Underwriter
Warrants to Purchase up to Shares of Common Stock
Shares
of Common Stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants
Shares
of Common Stock issuable upon exercise of the Underwriter Warrants
We
are offering up to shares of our common stock and common warrants to purchase
an aggregate of shares of our common stock (and the shares of common
stock that are issuable from time to time upon exercise of the common warrants). We are also offering to certain purchasers whose purchase
of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related
parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately
following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants to purchase
shares of our common stock, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership
exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable
for one share of our common stock. The purchase price of each pre-funded warrant and accompanying common warrant will be equal to the
price at which a share of common stock and accompanying common warrant are sold to the public in this offering, minus $0.0001, and the
exercise price of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will be immediately exercisable and may
be exercised at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common
stock issuable upon exercise of any pre-funded warrants sold in this offering. Each share of common stock and pre-funded warrant is being
sold together with a common warrant to purchase
share of our common stock at an exercise price of $ per share (representing % of the price at which a share of common stock and accompanying
common warrant are sold to the public in this offering). The common warrants will be exercisable immediately and will expire
years from the date of issuance. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be
decreased on a one-for-one basis. Because we will issue common warrant for each share of our common stock and for each pre-funded warrant
to purchase one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change
as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. The shares of common stock and pre-funded
warrants, and the accompanying common warrants, can only be purchased together in this offering but will be issued separately and will
be immediately separable upon issuance.
Our
common stock is listed on The Nasdaq Capital Market under the symbol “SONN.” On September 18, 2023 the last reported sale
price of our common stock on The Nasdaq Capital Market was $3.53 per share. There is no established public trading market for
the pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of the pre-funded
warrants on any national securities exchange. Without an active trading market, the liquidity of the pre-funded warrants will be limited.
The
public offering price per share of common stock and accompanying common warrant and any pre-funded warrant and accompanying common warrant,
as the case may be, will be determined by us at the time of pricing, may be at a discount to the current market price, and the recent
market price used throughout this prospectus may not be indicative of the final offering price.
You
should read this prospectus, together with additional information described under the headings “Information Incorporated by Reference”
and “Where You Can Find More Information,” carefully before you invest in any of our securities.
Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus and in the documents
incorporated by reference into this prospectus for a discussion of risks that should be considered in connection with an investment in
our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
| |
Per Share | | |
Per Pre-Funded Warrant | | |
Per Common Warrant | | |
Total | |
Public offering price | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
Underwriting discounts and commissions (1) | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
Proceeds to us, before expenses | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
(1)
See “Underwriting” for additional information regarding underwriting compensation.
We
have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to an additional ________
shares of common stock and/or additional common warrants
to purchase up to ________ shares of common stock from us, in any combination thereof, at the public offering price per share per common warrant, less the underwriting discounts and commissions.
The
delivery of the securities offered hereby to purchasers is expected to be made on or about _________, 2023.
Joint
Book-Running Managers
Chardan |
Ladenburg Thalmann |
The
date of this prospectus is __________, 2023.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
We
incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without
charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus
as well as additional information described under “Information Incorporated by Reference,” before deciding to invest in our
securities.
Neither
we nor the underwriters have authorized anyone to provide you with additional information or information different from that contained
or incorporated by reference in this prospectus filed with the Securities and Exchange Commission (the “SEC”). We take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The underwriters
are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information
contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those
respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition,
results of operations and prospects may have changed since that date.
The
information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating
to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and
research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications,
studies and surveys generally state that they have been obtained from sources believed to be reliable. While we believe our internal
company research is reliable and the definitions of our market and industry are appropriate, neither this research nor these definitions
have been verified by any independent source.
For
investors outside the United States (“U.S.”): We and the underwriters have not done anything that would permit this offering
or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the
U.S. Persons outside the U.S. who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the securities and the distribution of this prospectus outside of the U.S.
CAUTIONARY
NOTE CONCERNING FORWARD-LOOKING STATEMENTS
This
prospectus contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. All statements contained in this prospectus other than statements of historical
fact, including statements regarding our strategy, future operations, future financial position, liquidity, future revenue, projected
expenses, results of operations, expectations concerning the timing and our ability to commence and subsequently report data from planned
non-clinical studies and clinical trials, prospects, plans and objectives of management are forward-looking statements. The words “believe,”
“may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,”
or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s
current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected
in the forward-looking statements as a result of many factors.
We
based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe
may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives,
and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those
described in “Risk Factors” in this prospectus, and under a similar heading in any other annual, periodic or current report
incorporated by reference into this prospectus or that we may file with the SEC in the future. Moreover, we operate in a very competitive
and rapidly changing environment. New risks emerge quickly and from time to time. It is not possible for our management to predict all
risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks,
uncertainties and assumptions, the future events and trends discussed in this prospectus, may not occur and actual results could differ
materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or
publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in
their entirety by this cautionary statement.
You
should also read carefully the factors described in the “Risk Factors” section of this prospectus, and under a similar heading
in any other annual, periodic or current report incorporated by reference into this prospectus, to better understand the risks and uncertainties
inherent in our business and underlying any forward-looking statements. You are advised to consult any further disclosures we make on
related subjects in our future public filings.
PROSPECTUS
SUMMARY
This
summary highlights information about our company, this offering and information contained in greater detail in other parts of this prospectus
or incorporated by reference into this prospectus from our filings with the SEC listed in the section entitled “Information Incorporated
by Reference.” Because it is only a summary, it does not contain all of the information that you should consider before purchasing
our securities in this offering and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information
appearing elsewhere or incorporated by reference into this prospectus. You should read the entire prospectus, the registration statement
of which this prospectus is a part, and the information incorporated by reference into this prospectus in their entirety, including the
“Risk Factors” and our financial statements and the related notes incorporated by reference into this prospectus, before
purchasing our securities in this offering.
Except
as otherwise indicated herein or as the context otherwise requires, references in this prospectus to “the Company,” “we,”
“us” and “our” refer to Sonnet BioTherapeutics Holdings, Inc. and our consolidated subsidiaries.
On
August 31, 2023, we effected a reverse stock split of our issued and outstanding common stock, par value $0.0001 per share, at a ratio
of 1-for-22 and on September 16, 2022, we effected a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-14.
All of our historical share and per share information related to issued and outstanding common stock and outstanding options and warrants
exercisable for common stock included in this prospectus have been adjusted, on a retroactive basis, to reflect the reverse stock splits.
The information dated before August 31, 2023 incorporated by reference into this prospectus has not been adjusted to reflect the reverse
stock splits. See “Corporate Information.”
Corporate
Overview
Sonnet
BioTherapeutics Holdings, Inc. (“we,” “us,” “our” or the “Company”), is a clinical stage,
oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single- or bi-specific action.
Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment that
binds to and “hitch-hikes” on human serum albumin for transport to target tissues. We designed the construct to improve drug
accumulation in specific tissues, as well as to extend the duration of activity in the body. FHAB development candidates are
produced in a mammalian cell culture, which enables glycosylation, thereby reducing the risk of immunogenicity. We believe our FHAB
technology, for which we received a U.S. patent in June 2021, is a distinguishing feature of our biopharmaceutical platform that is well
suited for future drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory,
and hematological conditions.
Recent
Developments
Registered
Direct Offering and Private Placement
On
June 28, 2023, we entered into a securities purchase agreement with certain investors pursuant to which we agreed
to sell and issue, in (i) a registered direct offering (the “RD Offering”), an aggregate of (a) 166,363 shares of common
stock at a purchase price of $9.90 per share and accompanying Private Warrant, and (b) 60,909 pre-funded warrants (the “Pre-Funded
Warrants”) to purchase up to an aggregate of 60,909 shares of common stock (the “Pre-Funded Warrant Shares”) at a purchase
price of $9.8978 per Pre-Funded Warrant and accompanying Private Warrant and (ii) in a concurrent private placement (the “Private
Placement” and together with the RD Offering, the “June 2023 Offering”), Private Warrants to purchase up to 227,272
shares of common stock. The Private Warrants will be exercisable as of December 30, 2023 at an exercise price of $14.8478 per share and
will expire three and one-half years from the date of issuance. The closing of the issuance and sale of these securities was consummated
on June 30, 2023. The gross proceeds from the offering, prior to deducting offering expenses and placement agent fees and expenses payable
by us, was approximately $2.25 million.
Pursuant
to a placement agency agreement dated as of June 28, 2023, we engaged Chardan Capital Markets, LLC (“Chardan”) to act as
our exclusive placement agent in connection with the June 2023 Offering. We paid to Chardan (i) a cash fee equal to 8.0% of the aggregate
gross proceeds of the June 2023 Offering, excluding the proceeds, if any, from the exercise of the Private Warrants and (ii) a non-accountable
expense allowance of 0.5% of the aggregate gross proceeds of the June 2023 Offering, and (iii) reimbursed Chardan for certain expenses
and legal fees up to $35,000. In addition, we issued to Chardan or its designees, PA Warrants to purchase up to 6,818 shares of common
stock. The PA Warrants will be exercisable as of December 30, 2023 and have a term of exercise equal to three and a half years from the
date of issuance, with an exercise price of $14.8478 per share.
Corporate
Information
We
were organized on October 21, 1999, under the name Tulvine Systems, Inc., under the laws of the State of Delaware. On April 25, 2005,
Tulvine Systems, Inc. formed a wholly owned subsidiary, Chanticleer Holdings, Inc., and on May 2, 2005, Tulvine Systems, Inc. merged
with, and changed its name to, Chanticleer Holdings, Inc. On April 1, 2020, we completed our business combination with Sonnet BioTherapeutics,
Inc. (“Sonnet”), in accordance with the terms of the Agreement and Plan of Merger, dated as of October 10, 2019, as amended,
by and among us, Sonnet and Biosub Inc., a wholly-owned subsidiary of the Company (“Merger Sub”) (the “Merger Agreement”),
pursuant to which Merger Sub merged with and into Sonnet, with Sonnet surviving as a wholly owned subsidiary of us (the “Merger”).
Under the terms of the Merger Agreement, we issued shares of common stock to Sonnet’s stockholders at an exchange rate of 0.106572
shares for each share of Sonnet common stock outstanding immediately prior to the Merger. In connection with the Merger, we changed our
name from “Chanticleer Holdings, Inc.” to “Sonnet BioTherapeutics Holdings, Inc.,” and the business conducted
by us became the business conducted by Sonnet.
On
August 31, 2023, we effected a reverse stock split of our issued and outstanding common stock, par value $0.0001 per share, at a ratio
of 1-for-22 (the “2023 Reverse Stock Split”), and on September 16, 2022, we effected a reverse stock split of our issued
and outstanding common stock at a ratio of 1-for-14 (the “2022 Reverse Stock Split” and, together with the 2023 Reverse Stock
Split, the “Reverse Stock Splits”). Shares of common stock underlying outstanding stock options and other equity instruments
convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased
in accordance with the terms of the agreements governing such securities in connection with the Reverse Stock Splits. No fractional shares
were issued in connection with the Reverse Stock Splits. Stockholders who would otherwise be entitled to a fractional share of common
stock instead receive a proportional cash payment. All of our historical share and per share information related to issued and outstanding
common stock and outstanding options and warrants exercisable for common stock included in this prospectus have been adjusted, on a retroactive
basis, to reflect the Reverse Stock Splits. The information dated before August 31, 2023 incorporated by reference into this prospectus
has not been adjusted to reflect the 2023 Reverse Stock Split.
Our
principal executive offices are located at 100 Overlook Center, Suite 102, Princeton, New Jersey 08540, and our telephone number is (609)
375-2227. Our website is www.sonnetbio.com. Our website and the information contained on, or that can be accessed through, our website
shall not be deemed to be incorporated by reference in, and are not considered part of, this prospectus supplement or the accompanying
prospectus. You should not rely on any such information in making your decision whether to purchase our common stock.
The
Offering
Common
Stock to be Offered |
|
shares (or
shares if the underwriters’ option to purchase additional shares is exercised in full), based on the sale of our common
stock at an assumed combined public offering price of $ per share of common stock and accompanying common warrant, which is the last
reported sale price of our common stock on , 2023, and assuming no sale of any pre-funded warrants. |
|
|
|
Pre-funded
Warrants to be Offered |
|
We
are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser,
together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser,
9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if such
purchasers so choose, pre-funded warrants to purchase shares of common stock, in lieu of shares of common stock that would otherwise
result in any such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding
common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded
warrant and accompanying common warrant will equal the price at which the share of common stock and accompanying common warrant are
being sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant will be $0.0001 per share.
The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are
exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold
in this offering. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on
a one-for-one basis. Because we will issue common warrant for each share of our common stock and for each pre-funded warrant to purchase
one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change as a result
of a change in the mix of the shares of our common stock and pre-funded warrants sold. |
|
|
|
Common
Warrants to be Offered |
|
Common
warrants to purchase an aggregate of shares of our
common stock (or shares if the underwriters’ option to
purchase additional common warrants is exercised in full), based on the sale of our common stock at an assumed combined public
offering price of $ per share of common stock and accompanying common warrant, which is the last reported sale price of our common
stock on The Nasdaq Capital Market on , 2023. Each share of our common stock and each pre-funded warrant to purchase one share of
our common stock is being sold together with a common warrant to purchase
share of our common stock. Each common warrant will have an
exercise price of $ per share (representing % of the price at which a share of common stock and accompanying common warrant are sold
to the public in this offering), will be immediately exercisable and will expire on the
anniversary of the original issuance date. The shares of common
stock and pre-funded warrants, and the accompanying common warrants, as the case may be, can only be purchased together in this
offering but will be issued separately and will be immediately separable upon issuance. This prospectus also relates to the offering
of the shares of common stock issuable upon exercise of the common warrants. |
Common
Stock to be Outstanding Immediately After this Offering (1) |
|
shares
(or shares if the underwriters’ option to purchase additional shares is exercised in full), assuming in each case none of the
common warrants issued in this offering are exercised, and based on the sale of our common stock at an assumed combined public offering
price of $ per share of common stock, which is the last reported sale price of our common stock on The Nasdaq Capital Market on ,
2023, and no sale of any pre-funded warrants. |
|
|
|
Option
to Purchase Additional Securities |
|
We
have granted the underwriters an option, exercisable within 30 days after the closing of this offering, to acquire up to an additional
________ shares of common stock and/or additional
common warrants to purchase up to ________ shares of common stock from us, in any combination thereof, at the public offering price
per share, per common warrant, less the underwriting discounts and commissions, based on
the sale of our common stock at an assumed combined public offering price of $ per share of common stock, which is the last reported
sale price of our common stock on the Nasdaq Capital Market on , 2023, on the same terms as set forth in this prospectus. |
|
|
|
Underwriter
Warrants to be Offered |
|
We
have agreed to issue to the underwriters warrants (the “underwriter warrants”) to purchase up to shares of common stock
(representing 3% of the aggregate number of shares sold in this offering, including upon any exercise of the underwriters’
option to purchase additional shares of common stock, and including the number of shares of common stock underlying the pre-funded
warrants), at an exercise price of $ per share (representing 125% of
the price at which a share of common stock and accompanying common warrant are sold to the public in this offering). The underwriter
warrants will be exercisable immediately and for five years from the date of commencement of sales in this offering. The issuance
of the underwriter warrants and the shares issuable upon exercise of the underwriter warrants are registered on the registration
statement of which this prospectus forms a part. |
|
|
|
Use
of Proceeds |
|
We
estimate that the net proceeds from this offering will be approximately $ million, or $
million if the underwriters exercise their option to purchase additional securities in
full, based on an assumed combined public offering price of $ per share of common stock and
accompanying common warrant, which was the last reported sales price of our common stock
on The Nasdaq Capital Market on , 2023, and assuming no sale of any pre-funded warrants,
after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us, and excluding the proceeds, if any, from the exercise of the common warrants
in this offering.
We
currently intend to use the net proceeds from this offering for research and development, including clinical trials, working capital
and general corporate purposes. See “Use of Proceeds” for additional information. |
Risk
Factors |
|
An
investment in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus
and the other information included and incorporated by reference in this prospectus for a discussion of the risk factors you should
carefully consider before deciding to invest in our securities. |
|
|
|
National
Securities Exchange Listing |
|
Our
common stock is listed on The Nasdaq Capital Market under the symbol “SONN.” There is no established public trading market
for the pre-funded warrants or common warrants, and we do not expect a market to develop. In addition, we do not intend to apply
to list the pre-funded warrants or common warrants on any national securities exchange or other nationally recognized trading system.
Without an active trading market, the liquidity of the pre-funded warrants or common warrants will be limited. |
(1)
The number of shares of our common stock that will be outstanding immediately after this offering is based on 1,750,426 shares of common
stock outstanding as of September 11, 2023, and assumes the sale and issuance by us of _____________ shares of common stock (and no sale
of any pre-funded warrants) in this offering and excludes:
●
2,326 shares of common stock underlying restricted stock units outstanding as of September 11, 2023;
●
14,480 shares of common stock reserved for future issuance under the 2020 Omnibus Equity Incentive Plan as of September 11, 2023;
●
730,333 shares of common stock issuable upon the exercise of warrants outstanding as of September 11, 2023, with a weighted average
exercise price of $115.60 per share;
●
shares of common stock issuable upon the exercise of the pre-funded warrants issued in this offering, if any;
●
up to ______ shares (or shares if the underwriters’ option to purchase additional common warrants is exercised in full) of
common stock issuable upon the exercise of the common warrants issued in this offering; and
●
______ shares of common stock issuable upon the exercise of the underwriter warrants issued in this offering.
Unless
otherwise indicated, this prospectus reflects and assumes no issuances or exercises of any other outstanding shares, options or warrants
after September 11, 2023 and no exercise by the underwriters of their option to purchase additional shares.
RISK
FACTORS
Investing
in our securities involves a high degree of risk. We urge you to carefully consider all of the information contained in this prospectus
and other information which may be incorporated by reference in this prospectus as provided under “Information Incorporated by
Reference.” In particular, you should consider the risk factors below, together with those under the heading “Risk Factors”
in our most recent Annual Report on Form 10-K, which is incorporated by reference into this prospectus, as those risk factors are amended
or supplemented by our subsequent filings with the SEC. These risks and uncertainties are not the only risks and uncertainties we face.
Additional risks and uncertainties not currently known to us, or that we currently view as immaterial, may also impair our business.
If any of the risks or uncertainties described below or in our SEC filings or any additional risks and uncertainties actually occur,
our business, financial condition, results of operations and cash flow could be materially and adversely affected. As a result, you could
lose all or part of your investment.
RISKS
RELATED TO THIS OFFERING
If
you purchase shares of common stock in this offering, you will experience immediate and substantial dilution in your investment. You
will experience further dilution if we issue additional equity or equity-linked securities in the future.
Because
the price per share of our common stock being offered is substantially higher than the as adjusted net tangible book value per share
of our common stock, you will suffer immediate and substantial dilution with respect to the net tangible book value of the common stock
you purchase in this offering. Based on an assumed combined public offering price of $ per share of common stock and accompanying common
warrant being sold in this offering, and our as adjusted net tangible book value as of June 30, 2023 of $ per share, if you purchase
shares of common stock in this offering, you will suffer immediate and substantial dilution of $ per share with respect to the as adjusted
net tangible book value of the common stock. See the section entitled “Dilution” for a more detailed discussion of the dilution
you will incur if you purchase common stock in this offering.
If
we issue additional shares of common stock, or securities convertible into or exchangeable or exercisable for shares of common stock,
our stockholders, including investors who purchase shares of common stock and/or pre-funded warrants and accompanying common warrants
in this offering, will experience additional dilution, and any such issuances may result in downward pressure on the price of our common
stock. We also cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that
is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities
in the future could have rights superior to existing stockholders.
Future
sales of substantial amounts of our common stock or securities convertible into or exchangeable or exercisable for shares of common stock,
either by us or by our existing stockholders, or the possibility that such sales could occur, could adversely affect the market price
of our common stock.
Future
sales in the public market of shares of our common stock or securities convertible into or exchangeable or exercisable for shares of
common stock, including shares referred to in the foregoing risk factor, shares held by our existing stockholders or shares issued upon
exercise of our outstanding stock options or warrants, or the perception by the market that these sales could occur, could lower the
market price of our common stock or make it difficult for us to raise additional capital.
There
is no public market for the pre-funded warrants or common warrants being offered in this offering.
There
is no established public trading market for the pre-funded warrants or common warrants being offered in this offering, and we do not
expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants or common warrants on any securities
exchange or nationally recognized trading system, including The Nasdaq Capital Market. Without an active market, the liquidity of the
pre-funded warrants and common warrants will be limited.
Holders
of pre-funded warrants and common warrants purchased in this offering will have no rights as common stockholders until such holders exercise
such warrants and acquire our common stock.
Until
holders of pre-funded warrants or common warrants acquire shares of our common stock upon exercise of such warrants, holders of pre-funded
warrants or common warrants will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise
of the pre-funded warrants or common warrants, the holders will be entitled to exercise the rights of a common stockholder only as to
matters for which the record date occurs after the exercise date.
We
will have broad discretion in the use of our existing cash and cash equivalents, including the proceeds from this offering, and may invest
or spend our cash in ways with which you do not agree and in ways that may not increase the value of your investment.
We
will have broad discretion over the use of our cash and cash equivalents, including the proceeds from this offering. You may not agree
with our decisions, and our use of cash may not yield any return on your investment. We intend to use the net proceeds from this offering
for research and development, including clinical trials, working capital and general corporate purposes. Our failure to apply the net
proceeds from this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield
a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on
how to use our net proceeds from this offering.
USE
OF PROCEEDS
We
estimate that we will receive net proceeds of approximately $ million from the sale of the securities offered by us in this offering,
or approximately $ million if the underwriters exercise their option to purchase additional securities in full, based on an assumed combined
public offering price of $ per share and accompanying common warrant, which was the last reported sales price of our common stock on
The Nasdaq Capital Market on , 2023, after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us, excluding the proceeds, if any, from the exercise of the common warrants issued in this offering.
The
foregoing discussion assumes no sale of pre-funded warrants, which if sold, would reduce the number of shares of common stock that we
are offering on a one-for-one basis.
We
currently intend to use the net proceeds from this offering for research and development, including clinical trials, working capital
and general corporate purposes. See “Risk Factors” for a discussion of certain risks that may affect our intended use of
the net proceeds from this offering.
Our
expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition.
As of the date of this prospectus, we cannot currently allocate specific percentages of the net proceeds that we may use for the purposes
specified above, and we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion
of this offering, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of
the net proceeds will vary depending on numerous factors, including our ability to obtain additional financing, the progress, cost and
results of our preclinical and clinical development programs, and whether we are able to enter into future licensing or collaboration
arrangements.
Pending
the use of the net proceeds from this offering, we intend to invest the net proceeds in investment-grade, interest-bearing instruments,
certificates of deposit or direct or guaranteed obligations of the U.S.
A
$0.50 increase or decrease in the assumed public offering price of $ per share would increase or decrease the net proceeds to us from
this offering by approximately $ million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by
us.
Similarly,
a 0.5 million share increase or decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would
increase or decrease the net proceeds to us by approximately $ million, based on the assumed public offering price of $ per share remaining
the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
DILUTION
If
you invest in our securities, your ownership interest will be diluted to the extent of the difference between the public offering price
per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after the closing
of this offering.
Our
historical net tangible book value as of June 30, 2023 was $3.4 million, or $1.959 per share of common stock. Our historical net tangible
book value is the amount of our total tangible assets less our liabilities. Historical net tangible book value per common share is our
historical net tangible book value divided by the number of shares of common stock outstanding as of June 30, 2023.
After
giving effect to the sale of shares of common stock and the accompanying common warrants in this offering at an assumed combined public
offering price of $ per share and accompanying common warrant, which was the last reported sale price of our common stock on The Nasdaq
Capital Market on , 2023, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us, excluding the proceeds, if any, from the exercise of the common warrants issued in this offering, and assuming no sale of pre-funded
warrants in this offering, our as adjusted net tangible book value as of June 30, 2023 would be $ million, or $ per share of common stock.
This amount represents an immediate increase in net tangible book value of $ per share to our existing stockholders and an immediate
dilution of $ per share to investors participating in this offering. We determine dilution per share to investors participating in this
offering by subtracting as adjusted net tangible book value per share after this offering from the assumed combined public offering price
per share paid by investors participating in this offering.
The
following table illustrates this dilution on a per share basis to new investors:
Assumed combined public offering price per share and accompanying common warrant | |
| | | $ |
|
|
Historical net tangible book value per share as of June 30, 2023 | |
$ | 1.959 | |
|
|
|
Increase in net tangible book value per share attributable to this offering | |
| | |
|
|
|
Net tangible book value per share after giving effect to this offering | |
| | |
|
|
|
Dilution per share to new investors in this offering | |
| | | $ |
|
|
Each
$0.50 increase or decrease in the assumed combined public offering price of $ per share and accompanying common warrant, which was the
last reported sale price of our common stock on The Nasdaq Capital Market on , 2023, would increase or decrease the as adjusted net tangible
book value per share by $ per share and the dilution per share to investors participating in this offering by $ per share, respectively,
assuming that the number of shares and/or pre-funded warrants offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We
may also increase or decrease the number of shares we are offering. An increase of 0.5 million in the number of shares offered by us,
as set forth on the cover page of this prospectus, would increase the as adjusted net tangible book value per share by approximately
$ and decrease the dilution per share to new investors participating in this offering by approximately $ , based on an assumed combined
public offering price of $ per share and accompanying common warrant, which was the last reported sale price of our common stock on The
Nasdaq Capital Market on , 2023, remaining the same and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. A reduction of 0.5 million in the number of shares offered by us, as set forth on the cover page of
this prospectus, would decrease the as adjusted net tangible book value per share after this offering by approximately $ and increase
the dilution per share to new investors participating in this offering by approximately $ , based on an assumed combined public offering
price of $ per share and accompanying common warrant, which was the last reported sale price of our common stock on The Nasdaq Capital
Market on , 2023, remaining the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us.
If
the underwriters exercise their option to purchase additional shares in full, the as adjusted net tangible book value per share after
giving effect to this offering would be $ per share, which amount represents an immediate increase in the net tangible book value of
$ per share of our common stock to existing stockholders and an immediate dilution in net tangible book value of $ per share of our common
stock to new investors purchasing shares and accompanying common warrants in this offering.
The
table and discussion above is based on 1,744,984 shares of common stock outstanding as of June 30, 2023 and excludes:
●
2,326 shares of common stock underlying unvested restricted stock units outstanding as of June 30, 2023;
●
5,516 shares of common stock subject to restricted stock awards granted as of June 30, 2023 but not yet issued;
●
14,480 shares of common stock reserved for future issuance under the 2020 Omnibus Equity Incentive Plan as of June 30, 2023;
●
730,333 shares of common stock issuable upon the exercise of warrants outstanding as of June 30, 2023, with a weighted average exercise
price of $115.60 per share;
●
shares of common stock issuable upon the exercise of the pre-funded warrants issued in this offering;
●
shares of common stock issuable upon the exercise of the common warrants issued in this offering; and
●
shares of common stock issuable upon the exercise of the underwriter warrants issued in this offering.
The
information discussed above is illustrative only and will adjust based on the actual public offering price, the actual number of shares
and common warrants that we offer in this offering, and other terms of this offering determined at pricing. Except as indicated otherwise,
the discussion and table above assume (i) no sale of pre-funded warrants, which, if sold, would reduce the number of shares of common
stock that we are offering on a one-for-one basis, (ii) no exercise of the underwriters’ option to purchase additional shares and
(iii) no exercise of common warrants accompanying the shares of common stock sold in this offering.
DESCRIPTION
OF CAPITAL STOCK
Our
authorized capital stock consists of:
●
125,000,000 shares of common stock, par value $0.0001 per share; and
●
5,000,000 shares of preferred stock, par value $0.0001 per share, of which, as of the date of this prospectus, none of which shares have
been designated.
As
of close of business on September 11, 2023, 1,750,426 shares of common stock were issued and outstanding and no shares of preferred stock
were issued and outstanding.
The
additional shares of our authorized stock available for issuance may be issued at times and under circumstances so as to have a dilutive
effect on earnings per share and on the equity ownership of the holders of our common stock. The ability of our board of directors to
issue additional shares of stock could enhance the board’s ability to negotiate on behalf of the stockholders in a takeover situation
but could also be used by the board to make a change-in-control more difficult, thereby denying stockholders the potential to sell their
shares at a premium and entrenching current management. The following description is a summary of the material provisions of our capital
stock. You should refer to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and Amended
and Restated Bylaws (the “Bylaws”), both of which are on file with the SEC as exhibits to previous SEC filings, for additional
information. The summary below is qualified by provisions of applicable law.
Common
Stock
Holders
of our common stock are each entitled to cast one vote for each share held of record on all matters presented to stockholders. Cumulative
voting is not allowed; the holders of a majority of our outstanding shares of common stock may elect all directors. Holders of our common
stock are entitled to receive such dividends as may be declared by our board out of funds legally available and, in the event of liquidation,
to share pro rata in any distribution of our assets after payment of liabilities. Our directors are not obligated to declare a dividend.
It is not anticipated that we will pau dividends in the foreseeable future. Holders of our do not have preemptive rights to subscribe
to any additional shares we may issue in the future. There are no conversion, redemption, sinking fund or similar provisions regarding
the common stock. All outstanding shares of common stock are fully paid and nonassessable.
The
rights, preferences and privileges of holders of common stock are subject to the rights of the holders of any outstanding shares of preferred
stock.
Preferred
Stock
We
are authorized to issue up to 5,000,000 shares of preferred stock, all of which are undesignated. Our board of directors has the authority
to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications,
limitations or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences
and the number of shares constituting any class or series, without further vote or action by the stockholders. Although we have no present
plans to issue any other shares of preferred stock, the issuance of shares of preferred stock, or the issuance of rights to purchase
such shares, could decrease the amount of earnings and assets available for distribution to the holders of common stock, could adversely
affect the rights and powers, including voting rights, of the common stock, and could have the effect of delaying, deterring or preventing
a change of control of us or an unsolicited acquisition proposal. The preferred stock may provide for an adjustment of the conversion
price in the event of an issuance or deemed issuance at a price less than the applicable conversion price, subject to certain exceptions.
If
we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus
supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the
extent required, this description will include:
●
the title and stated value;
●
the number of shares offered, the liquidation preference per share and the purchase price;
●
the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;
●
whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
●
the procedures for any auction and remarketing, if any;
●
the provisions for a sinking fund, if any;
●
the provisions for redemption, if applicable;
●
any listing of the preferred stock on any securities exchange or market;
●
whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated)
and conversion period;
●
whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated)
and exchange period;
●
voting rights, if any, of the preferred stock;
●
a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock;
●
the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding
up of our affairs; and
●
any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred
stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs.
Anti-takeover
Effects of Delaware Law and our Certificate of Incorporation and Bylaws
Our
Certificate of Incorporation and Bylaws contain provisions that could have the effect of discouraging potential acquisition proposals
or tender offers or delaying or preventing a change of control. These provisions are as follows:
●
they provide that special meetings of stockholders may be called by the President, the board of directors or at the request by stockholders
of record owning at least thirty-three and one-third (33 1/3%) percent of the issued and outstanding voting shares of our common stock;
●
they do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority stockholder holding
a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative voting may have
the effect of limiting the ability of minority stockholders to effect changes in our board of directors; and
●
they allow us to issue, without stockholder approval, up to 5,000,000 shares of preferred stock that could adversely affect the rights
and powers of the holders of our common stock.
We
are subject to the provisions of Section 203 of the Delaware General Corporation Law, an anti-takeover law. Subject to certain exceptions,
the statute prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested
stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder
unless:
●
prior to such date, the board of directors of the corporation approved either the business combination or the transaction which resulted
in the stockholder becoming an interested stockholder;
●
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least eighty-five percent 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding
for purposes of determining the number of shares outstanding those shares owned (1) by persons who are directors and also officers and
(2) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject
to the plan will be tendered in a tender or exchange offer; or
●
on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
of stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-thirds percent 66 2/3% of the outstanding
voting stock that is not owned by the interested stockholder.
Generally,
for purposes of Section 203, a “business combination” includes a merger, asset or stock sale, or other transaction resulting
in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates
and associates, owns or, within three (3) years prior to the determination of interested stockholder status, owned fifteen percent (15%)
or more of a corporation’s outstanding voting securities.
Potential
Effects of Authorized but Unissued Stock
We
have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional
shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions
or payment as a dividend on the capital stock.
The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly
to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to
obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.
In addition, the board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including
voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock,
all to the fullest extent permissible under the DGCL and subject to any limitations set forth in our Certificate of Incorporation. The
purpose of authorizing the board of directors to issue preferred stock and to determine the rights and preferences applicable to such
preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while
providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect
of making it more difficult for a third-party to acquire, or could discourage a third-party from acquiring, a majority of our outstanding
voting stock.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is Securities Transfer Corporation. The transfer agent address is Securities Transfer
Corporation, 2901 N Dallas Parkway, Suite 380, Plano, TX 75093, (469) 633-0101.
DESCRIPTION
OF SECURITIES WE ARE OFFERING
We
are offering (i) shares of our common stock or pre-funded warrants to purchase shares of our common stock and (ii) common warrants to
purchase up to an aggregate of shares of our common stock. Each share of common stock or pre-funded warrant is being sold together with
a common warrant to purchase share of our common stock. The shares of common stock or pre-funded warrants and accompanying common warrants
will be issued separately. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded
warrants and common warrants offered hereby.
Common
Stock
The
material terms and provisions of our common stock are described under the caption “Description of Capital Stock” in this
prospectus.
Pre-Funded
Warrants
The
following summary of certain terms and provisions of pre-funded warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which will be filed as an exhibit to the
registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions
of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.
Duration
and Exercise Price. Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.0001. The pre-funded
warrants will be immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. The exercise
price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting our common stock and the exercise price. The pre-funded warrants will be issued
separately from the
accompanying
common warrants and may be transferred separately immediately thereafter.
Exercisability.
The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed
exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the
case of a cashless exercise as discussed below). Purchasers of the pre-funded warrants in this offering may elect to deliver their exercise
notice following the pricing of the offering and prior to the issuance of the pre-funded warrants at closing to have their pre-funded
warrants exercised immediately upon issuance and receive shares of common stock underlying the pre-funded warrants upon closing of this
offering. A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder
would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days’ prior
notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s
pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants
in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99%
of our outstanding common stock. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded
warrant. In lieu of fractional shares, we will round down to the next whole share.
Cashless
Exercise. If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares
of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available, then in lieu of making
the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may
elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according
to a formula set forth in the pre-funded warrants.
Transferability.
Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded
warrant to us together with the appropriate instruments of transfer.
Exchange
Listing. There is no trading market available for the pre-funded warrants on any securities exchange or nationally recognized trading
system. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system.
Right
as a Stockholder. Except as otherwise provided in the pre-funded warrants or by virtue of such holder’s ownership of shares
of our common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including
any voting rights, until they exercise their pre-funded warrants.
Fundamental
Transaction. In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization,
recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common
stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the
holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities,
cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental
transaction.
Common
Warrants
The
following summary of certain terms and provisions of common warrants that are being offered hereby is not complete and is subject to,
and qualified in its entirety by, the provisions of the common warrants, the form of which will be filed as an exhibit to the registration
statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of
common warrants for a complete description of the terms and conditions of the common warrants.
Duration
and Exercise Price. Each common warrant offered hereby will have an initial exercise price per share equal to $ . The common warrants
will be immediately exercisable and will expire on the anniversary of the original issuance date. The exercise price and number of shares
of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations
or similar events affecting our common stock and the exercise price. The common warrants will be issued separately from the common stock
(or pre-funded warrants) and may be transferred separately immediately thereafter. A common warrant to purchase share of our common stock
will be issued for every share of common stock (or pre-funded warrant to purchase a share of common stock) purchased in this offering.
Exercisability.
The common warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of
a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the common warrant to
the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at
least 61 days’ prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising
the holder’s common warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. No fractional shares
of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, we will round down
to the next whole share.
Cashless
Exercise. If, at the time a holder exercises its common warrants, a registration statement registering the issuance of the shares
of common stock underlying the common warrants under the Securities Act is not then effective or available and an exemption from registration
under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants.
Transferability.
Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant to us
together with the appropriate instruments of transfer.
Exchange
Listing. There is no established public trading market for the common warrants, and we do not expect a market to develop. In addition,
we do not intend to list the common warrants on any securities exchange or nationally recognized trading system. Without an active trading
market, the liquidity of the common warrants will be limited.
Right
as a Stockholder. Except as otherwise provided in the common warrants or by virtue of such holder’s ownership of shares of
our common stock, the holders of the common warrants do not have the rights or privileges of holders of our common stock, including any
voting rights, until they exercise their common warrants.
Fundamental
Transaction. In the event of a fundamental transaction, as described in the form of common warrant, and generally including any reorganization,
recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common
stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the
holders of the common warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash
or other property that the holders would have received had they exercised the common warrants immediately prior to such fundamental transaction.
UNDERWRITING
We
entered into an underwriting agreement with Chardan Capital Markets, LLC (“Chardan”) and Ladenburg Thalmann & Co.
Inc. (“Ladenburg”), as representatives of the several underwriters (the “Representatives”), relating to this offering. Subject
to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters and each of the underwriters has
agreed to purchase, severally and not jointly, the number of shares, pre-funded warrants and common warrants set forth opposite its name
in the following table:
| |
Number of Shares of Common Stock | | |
Number of Pre-Funded Warrants | | |
Number of Common Warrants | |
Chardan Capital Markets, LLC | |
| | | |
| | | |
| | |
Ladenburg Thalmann & Co. Inc. | |
| | | |
| | | |
| | |
TOTAL | |
| | | |
| | | |
| | |
The
underwriters have agreed to purchase all of the shares of common stock and/or pre-funded warrants and accompanying common warrants offered
by us, other than those covered by the underwriter’s option to purchase additional securities from us as described below, if any
are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting
agreement. Furthermore, pursuant to the underwriting agreement, the obligations of the underwriters are subject to customary conditions,
representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers’ certificates
and legal opinions.
The
underwriters have advised us that they propose initially to offer the shares of common stock and/or pre-funded warrants and accompanying
common warrants to purchase shares of common stock to the public at the public offering price set forth on the cover page of this prospectus
and to dealers at a price less a concession not in excess of $ per share and accompanying common warrant or $ per pre-funded
warrant and accompanying common warrant, based on the combined public offering price per share and accompanying common warrant or pre-funded
warrant and accompanying common warrant. After the shares of common stock and/or pre-funded warrants and accompanying common warrants
are released for sale to the public, the underwriters may change the offering price, the concession, and other selling terms at various
times.
We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act and to contribute
to payments the underwriters may be required to make in respect thereof.
The
underwriters are offering the securities in this offering subject to prior sale, when, as and if issued to and accepted by them subject
to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve
the right to withdraw, cancel or modify orders to the public, and to reject orders in whole or in part.
Over-Allotment
Option
We
have granted the underwriters an option, exercisable one or more times, in whole or in part, not later than 30 days from the date of
this prospectus, to purchase from us up to an additional shares of common stock and/or additional common warrants to purchase up to shares of common stock, in any combination thereof, at the public
offering price per share and public offering price per warrant, respectively, less the underwriting discounts and commissions solely
to cover over-allotments, if any.
Discounts,
Commissions and Reimbursement
The
following table provides information regarding the amount of the discounts and commissions to be paid to the underwriters by us. Such
amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional securities.
| |
Per Share and Accompanying Common Warrant | | |
Per Pre-Funded Warrant and Accompanying Common Warrant | | |
Total Without Exercise of Option | | |
Total With Full Exercise of Option | |
Public offering price | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
Underwriting discounts and commissions (1) | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
Proceeds to us, before expenses | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
(1)
We have agreed to pay the underwriters a commission of 7% of the gross proceeds of this offering.
We
have agreed to pay all reasonable out-of-pocket expenses of the underwriters relating to the offering:, including (a) all filing fees
and expenses relating to the registration of the shares of common stock, the pre-funded warrants and the common warrants with the SEC;
(b) all fees and expenses relating to the listing of the shares of common stock (including shares issuable upon exercise of the
common warrants and any pre-funded warrants on Nasdaq; (c) all fees, expenses and disbursements relating to the registration or qualification
of the the shares of common stock, the pre-funded warrants and the common warrants offered hereby under the “blue sky” securities
laws of such states and other jurisdictions as the Representatives may reasonably designate (including, without limitation, all
filing and registration fees, and the reasonable fees and disbursements of the Company’s “blue sky” counsel, which
will be counsel to the underwriters) unless such registrations or qualifications are not required in connection with the Offering; (d)
all fees, expenses and disbursements relating to the registration, qualification or exemption of the the shares of common stock, the
pre-funded warrants and the common warrants offered hereby under the securities laws of such foreign jurisdictions as the Representatives
may reasonably designate; (e) the costs of all mailing and printing of the offering documents (including the Underwriting Agreement,
any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers’ Agreement, Underwriters’ Questionnaire
and Power of Attorney), registration statements, prospectuses and all amendments, supplements and exhibits thereto and as many preliminary
and final prospectuses as the Representatives may reasonably deem necessary; (f) transfer and/or stamp taxes, if any, payable upon the transfer
of Company’s securities from the Company to the underwriters; (g) the fees and expenses of our accountants; (h) all filing fees
and communication expenses associated with the review of the offering by FINRA; (i) the expenses relating to “road show”
marketing trips; (j) the fees of legal counsel to the underwriters, in an amount not to exceed $65,000.
We
have also agreed to pay the Representatives at closing a non-accountable expense allowance equal to 1.0% of the gross proceeds
received by us from the sale of the shares, pre-funded warrants and common warrants.
We
estimate that our total expenses of the offering, excluding the estimated underwriting discounts and commissions, will be approximately
$ , which includes the fees and expenses for which we have agreed to reimburse the underwriters, provided that any such fees and expenses
will not exceed an aggregate of $75,000.
Underwriter
Warrants
We
have agreed to issue to the underwriters warrants (the “underwriter warrants”) to purchase up to shares of common stock (representing
3% of the aggregate number of shares sold in this offering, including upon any exercise of the underwriters’ option to purchase
additional shares of common stock, and including the number of shares of common stock underlying the pre-funded warrants), at an exercise
price of $ per share (representing 125% of the price at which a share of common stock and accompanying common warrant are sold to the
public in this offering). The underwriter warrants will be exercisable immediately and for five years from the date of commencement of
sales in this offering. The issuance of the underwriter warrants and the shares issuable upon exercise of the underwriter warrants are
registered on the registration statement of which this prospectus forms a part. The underwriter warrants shall not be redeemable. The
shares of common stock issuable upon exercise of the underwriter warrants may not be sold, transferred, assigned, pledged, or hypothecated,
or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition
of the securities by any person for a period of 180 days following the commencement of sales under the registration statement of which
this prospectus forms a part, except that they may be assigned, in whole or in part, to any officer or partner of the underwriters. The
underwriter warrants may be exercised as to all or a lesser number of shares of common stock for a period of five (5) years after the
commencement of sales under the registration statement of which this prospectus forms a part, will provide for cashless exercise in the
event an effective registration statement for the shares of common stock issuable upon exercise of the underwriter warrants is not available.
The underwriter warrants shall further provide for anti-dilution protection (adjustment in the number and price of such warrants and
the shares issuable upon exercise of such warrants) resulting from corporate events (which would include dividends, reorganizations,
mergers, etc.) when the public stockholders have been proportionally affected and otherwise in compliance with FINRA Rule 5110(f)(2)(G)(vi).
Lock-Up
Agreements
We
have agreed with the underwriters that we will not, without the prior written consent of the Representatives, for a period of 90 days
after the date of this prospectus: (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any classes of our stocks or any securities convertible into or exercisable or exchangeable for any classes of our stocks, (ii) file
or caused to be filed any registration statement with the SEC, relating to the offering of any classes of our stocks or any securities
convertible into or exercisable or exchangeable for any classes of our stocks, (iii) complete any offering of debt securities, other
than entering into a line of credit with a traditional bank, or (iv) enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of any classes of our stocks, whether any such transaction described
in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of any classes of our stocks or such other securities, in cash
or otherwise.
Tail
Period
In
the event that this offering is not consummated as contemplated herein, the underwriter will be entitled to receive a cash fee equal
to (a) seven percent (7.0%) of the gross proceeds received by us from any financing or capital raising transaction and (b) warrants to
purchase common stock equal to three percent (3%) of the number of shares of common stock sold in a subsequent offering, to the extent
that such proceeds are provided to us by any investor directly introduced by the underwriters to us during the period beginning on August
28, 2023 and ending on the earlier of the closing of the Offering or the earlier termination of the engagement (the “Engagement
Period”) and the transaction is consummated at any time during the Engagement Period or within the one-month month period following
the Engagement Period.
Discretionary
Accounts
The
underwriters do not intend to confirm sales of the shares of common stock, the pre-funded warrants and the common warrants offered hereby
to any accounts over which they have discretionary authority.
Electronic
Offer, Sale, and Distribution of Securities
A
prospectus in electronic format may be made available on the websites maintained by the underwriter. The prospectus in electronic format
will be identical to the paper version of such prospectus. The underwriter may agree to allocate a number of shares to underwriter and
selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriter
and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in
electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the registration
statement of which this prospectus forms a part, has not been approved or endorsed by us, and should not be relied upon by investors.
Listing
Our
common stock is listed on The Nasdaq Capital Market under the symbol “SONN.” On September 18, 2023, the last reported sale
price of our common stock on The Nasdaq Capital Market was $[ ] per share. There is no established public trading market for the pre-funded
warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of the pre-funded warrants on
any national securities exchange. Without an active trading market, the liquidity of the pre-funded warrants will be limited.
Stabilization
In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales.
|
● |
Stabilizing
transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged
in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress. |
|
|
|
|
● |
Over-allotment
transactions involve sales by the underwriter of securities in excess of the number of securities the underwriter is obligated to
purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered
short position, the number of securities over-allotted by the underwriter is not greater than the number of securities that they
may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number
of securities in the over-allotment option. The underwriter may close out any short position by exercising their over-allotment option
and/or purchasing securities in the open market. |
|
|
|
|
● |
Syndicate
covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover
syndicate short positions. In determining the source of securities to close out the short position, the underwriter will consider,
among other things, the price of securities available for purchase in the open market as compared with the price at which they may
purchase securities through exercise of the over-allotment option. If the underwriter sells more securities than could be covered
by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying
securities in the open market. A naked short position is more likely to be created if the underwriter is concerned that after pricing
there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase
in the offering. |
|
|
|
|
● |
Penalty
bids permit the underwriter to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate
member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. |
These
stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids may have the effect of raising
or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result,
the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither
we nor the underwriter make any representation or prediction as to the effect that the transactions described above may have on the price
of our securities. These transactions may be affected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and, if
commenced, may be discontinued at any time.
Passive
Market Making
In
connection with this offering, the underwriters and selling group members may engage in passive market making transactions in our securities
on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid
at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.
Certain
Relationships
The
underwriters and their affiliates have provided, or may in the future, from time to time, engage in transactions with and perform services
for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary
course of their various business activities, the underwriters and their affiliates may make or hold a broad array of investments and
actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their
own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments
of our Company. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent
research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long
and/or short positions in such securities and instruments.
INFORMATION
INCORPORATED BY REFERENCE
The
SEC allows us to “incorporate by reference” information into this document, which means that we can disclose important information
to you by referring you to another document filed separately with the SEC. The information incorporated by reference is an important
part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information.
We
incorporate by reference the documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14, or 15(d)
of the Exchange Act made subsequent to the date of this prospectus until the termination of the offering of the securities described
in this prospectus (other than information in such filings that was “furnished,” under applicable SEC rules, rather than
“filed”). We incorporate by reference the following documents or information that we have filed with the SEC:
●
our Annual Report on Form 10-K for the year ended September 30, 2022, filed with the SEC on December 15, 2022;
●
our Quarterly Reports on Form 10-Q for the fiscal quarters ended December 31, 2022, March 31, 2023, and June 30, 2023, filed with the
SEC on February 13, 2023, May 10, 2023, and August 14, 2023, respectively; and
●
our Current Reports on Form 8-K filed with the SEC on October 4, 2022, October 17, 2022, October 31, 2022, November 2, 2022, November 9, 2022, January 9, 2023, January 19, 2023, February 13, 2023, March 24, 2023, April 18, 2023, June 30, 2023, July 21, 2023, August 22, 2023, August 31, 2023 and September 1, 2023 (other than any portions thereof deemed furnished and not filed).
Any
statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this prospectus
will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement
to this prospectus, or document deemed to be incorporated by reference into this prospectus, modifies or supersedes such statement. Any
statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
You
may request a copy of these filings at no cost, by writing or telephoning us at the following address:
Sonnet
BioTherapeutics Holdings, Inc.
Attn:
Pankaj Mohan, Ph.D., CEO and Chairman
100
Overlook Center, Suite 102
Princeton,
New Jersey 08540
(609)
375-2227
You
may also access these filings on our website at www.sonnetbio.com. You should rely only on the information incorporated by reference
or provided in this prospectus. We have not authorized anyone else to provide different or additional information on our behalf. An offer
of these securities is not being made in any jurisdiction where the offer or sale is not permitted. You should not assume that the information
in this prospectus is accurate as of any date other than the date of those respective documents.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities
we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the
registration statement. You should rely only on the information contained in this prospectus or incorporated by reference into this prospectus.
We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any jurisdiction
where the offer is not permitted. You should assume that the information contained in this prospectus, or any document incorporated by
reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this
prospectus or any sale of our securities.
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public from commercial document retrieval services and over the Internet at the SEC’s website at http://www.sec.gov.
We
maintain a website at www.sonnetbio.com. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports
on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free
of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC.
The information contained in, or that can be accessed through, our website is not incorporated by reference into, and is not part of,
this prospectus.
LEGAL
MATTERS
The
validity of the common stock and certain other legal matters will be passed upon for us by Lowenstein Sandler LLP, New York, New York.
Lucosky Brookman LLP, Woodbridge, New Jersey, has acted as counsel to the underwriters in connection with this offering.
EXPERTS
The
consolidated financial statements of Sonnet BioTherapeutics Holdings, Inc. as of September 30, 2022 and 2021 and for the years then ended
have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated
by reference herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the September
30, 2022 consolidated financial statements contains an explanatory paragraph that states that Sonnet BioTherapeutics Holdings, Inc. has
incurred recurring losses and negative cash flows from operations since inception and will require substantial additional financing to
continue to fund its research and development activities that raise substantial doubt about its ability to continue as a going concern.
The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Up
to Shares of Common Stock
Pre-Funded
Warrants to Purchase up to Shares of Common
Stock
Common
Warrants to Purchase up to Shares of Common Stock
Underwriter
Warrants to Purchase up to Shares of Common
Stock
Shares
of Common Stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants
Shares
of Common Stock issuable upon exercise of the Underwriter Warrants
PROSPECTUS
Joint
Book-Running Managers
Chardan |
Ladenburg Thalmann |
The date of this prospectus is ________, 2023.
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by us in connection with
the sale and distribution of the securities being registered. All of the amounts shown are estimates, except for the SEC registration
fee and the FINRA filing fee:
|
|
Amount
to
be paid |
|
SEC
registration fee |
|
$ |
2,300 |
|
FINRA
filing fee |
|
|
* |
|
Legal
fees and expenses |
|
|
* |
|
Accounting
fees and expenses |
|
|
* |
|
Miscellaneous |
|
|
* |
|
Total
expenses |
|
$ |
* |
|
*
To be provided by amendment.
Item
14. Indemnification of Directors and Officers.
Section
145 of the Delaware General Corporation Law (the “DGCL”) provides, in general, that a corporation incorporated under the
laws of the State of Delaware, as we are, may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the
fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys’ fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding
if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the
corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was
unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys’
fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person
acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation,
except that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged
to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or any other court
in which such action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses.
Article
X of our Certificate of Incorporation states that to the fullest extent permitted by the DGCL, a director of the corporation shall not
be liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.
Under
Article VI of our Bylaws, any director, officer, employee or agent of the Company who was or is made or is threatened to be made a party
or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”)
by reason of the fact that such director, officer, employee or agent or a person for whom such director, officer, employee or agent is
the legal representative, is or was a director or officer of the Company or, while serving as a director, officer, employee or agent
of the Company, is or was serving at the request of the Company as a director, officer, employee or agent of another corporation or of
a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans (an “Indemnification
Covered Person”), against all liability and loss suffered and expenses (including attorneys’ fees, judgments, fines ERISA
excise taxes or penalties and amounts paid in settlement) reasonably incurred by such person in connection with any such Proceeding.
We
maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out
of claims based on acts or omissions in their capacities as directors or officers.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item
15. Recent Sales of Unregistered Securities.
In
the three years preceding the filing of this registration statement, the Company made sales of the following unregistered securities:
In
August 2022, we entered into a securities purchase agreement (the “Preferred SPA”) with several accredited investors for
the issuance and sale of (i) an aggregate of 22,275 shares of our Series 3 Convertible Preferred Stock, stated value $100 per share,
(ii) 225 shares of our Series 4 Convertible Preferred Stock, stated value $100 per share, and (iii) Series 3 warrants to purchase up
to 12,551 shares of our common stock in a private placement for aggregate gross proceeds of $2.3 million, with $0.1 million of issuance
costs for net proceeds of $2.1 million. The shares of Series 3 Convertible Preferred Stock were convertible into an aggregate of 24,852
shares of our common stock and the shares of Series 4 Convertible Preferred Stock were convertible into an aggregate of 251 shares of
our common stock, in each case, at a conversion price of $89.628 per share. The Series 3 warrants have an exercise price of $89.628 per
share, are exercisable commencing six months after issuance, and will expire five years from the issuance date. In September 2022, all
shares of preferred stock issued in connection with the Preferred SPA were converted into shares of common stock.
Pursuant
to a Securities Purchase Agreement (the “Securities Purchase Agreement”) dated February 7, 2020, by and among the Company,
Sonnet BioTherapeutics, Inc. (“Sonnet Sub”) and certain investors, for an aggregate purchase price of approximately $19.0
million (comprised of (I) a $4 million credit from Sonnet Sub and the Company to Chardan Capital Markets, LLC (“Chardan”),
in lieu of certain transaction fees otherwise owed to Chardan, and (II) $15 million in cash from the other Investors (the “Purchase
Price”), (i) Sonnet Sub issued and sold to the investors shares of Sonnet Sub’s common stock (the “Initial Shares”)
which converted in the merger among the Company and Sonnet Sub on April 1, 2020 into an aggregate of approximately 6,987 shares of the
Company’s common stock, (ii) the Company issued to the investors Series A Warrants (the “Series A Warrants”) to purchase
an aggregate of 10,714 shares of common stock at an exercise price of $1,662.54 per share and (iii) the Company issued to the investors
Series B Warrants (the “Series B Warrants”) to purchase an aggregate of 7,297 shares of common stock at an exercise price
of $0.0308 per share. The Company issued the warrants to the investors in reliance on the exemption from registration provided for under
Section 4(a)(2) of the Securities Act. The Company relied on this exemption from registration for private placements based in part on
the representations made by the investors, including the representations with respect to each investor’s status as an “accredited
investor,” as such term is defined in Rule 501(a) of the Securities Act, and the Investors’ investment intent.
On
August 3, 2020, the Company entered into Warrant Exercise and Omnibus Amendment Agreements (the “Exercise Agreements”) with
the holders of the Series A Warrants and Series B Warrants (the “Holders”). Pursuant to the Exercise Agreements, in order
to induce the Holders to exercise the Series A Warrants for cash, pursuant to the terms of the Series A Warrants, the Company agreed
to reduce the exercise price of the Series A Warrants from $1,662.54 to $982.52 per share. The Holders and the Company agreed that the
Holders would exercise all of their Series A Warrants for gross proceeds before expenses of approximately $10.5 million. In addition,
the Exercise Agreements also provide for the issuance to the Holders, Series C Warrants (the “Series C Warrants”) to purchase
3.4331 shares of common stock (the “Series C Warrant Shares”) for each share of common stock issued upon such exercise of
the Series A Warrants pursuant to the Exercise Agreements or an aggregate of 36,783 Series C Warrants. The terms of the Series C Warrants
are substantially similar to those of the Series A Warrants, except that the Series C Warrants have an exercise price of $982.52, do
not contain subsequent issuance price protection, were not exercisable until the date that was six months from the date of issuance of
each Series C Warrant and will expire on October 16, 2025. The Exercise Agreements provided for the amendment to each Holder’s
Series B Warrants to (i) remove the provisions providing for the rest of the number of shares of common stock underlying the Series B
Warrants and (ii) set the aggregate number of shares of common stock underlying all of the Series B Warrants at 14,715, which results
from an increase of 7,418 shares pursuant to the terms of the Exercise Agreements. The Company issued the Series B Warrants, the Series
C Warrants and the shares of common stock underlying the Series A Warrants, the Series B Warrants and the Series C Warrants to the Holders
in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act. The Company relied on this exemption
from registration for private placements based in part on the representations made by the Holders, including the representations with
respect to each Holder’s status as an “accredited investor,” as such term is defined in Rule 501(a) of the Securities
Act, and each Holder’s investment intent.
In
connection with a registered direct offering of our shares of common stock and pre-funded warrants to purchase shares of common stock,
on June 28, 2023, we entered into a securities purchase agreement with certain institutional investors (the “Purchasers”),
pursuant to which, among other things, we sold to the Purchasers warrants (the “Private Warrants”) to purchase up to 227,272
shares of common stock in a private placement. No separate consideration was paid for the issuance of the Private Warrants. In addition,
the Company issued to Chardan or its designees, warrants (“PA Warrants” and together with the Private Warrants, the “Warrants”)
to purchase up to 6,818 shares of common stock (the “PA Warrant Shares”). The Warrants will be exercisable as of December
30, 2023. The Warrants have a term of exercise equal to five years from the date of the securities purchase agreement and have an exercise
price equal to $14.8478 per share.
The
Warrants and the shares of common stock issuable upon exercise of the Warrants were offered pursuant to an exemption from the registration
requirement of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Rule 506 promulgated under Regulation D of
the Securities Act.
Item
16. Exhibits.
The
list of exhibits following the signature page of this registration statement is incorporated by reference herein.
Item
17. Undertakings.
(1) |
The
undersigned registrant hereby undertakes: |
|
(a) |
To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
|
(i) |
To
include any prospectus required by Section 10(a)(3) of the Securities Act; |
|
(ii) |
To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if,
in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price
set forth in the “Calculation of Registration Fee” table in the effective registration statement; and |
|
(iii) |
To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement; |
|
(b) |
That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof. |
|
(c) |
To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering. |
|
(d) |
That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant hereby undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the
securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will
be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
|
(i) |
Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424; |
|
(ii) |
Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant; |
|
(iii) |
The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and |
|
(iv) |
Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(2) |
The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference
in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) |
The
undersigned registrant hereby undertakes that: |
|
(a) |
For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part
of this registration statement in reliance on Rule 430A and contained in a form of prospectus filed by the undersigned registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as
of the time it was declared effective; and |
|
(b) |
For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. |
(4) |
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue. |
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized in the City of Princeton, State of New Jersey, on September 19, 2023.
|
SONNET
BIOTHERAPEUTICS HOLDINGS, INC. |
|
|
|
|
By: |
/s/
Pankaj Mohan |
|
|
Pankaj
Mohan
Chief
Executive Officer |
KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pankaj Mohan and Jay Cross, and
each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or
her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement,
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do
in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/
Pankaj Mohan |
|
Chief
Executive Officer and Chairman |
|
September
19, 2023 |
Pankaj
Mohan |
|
(Principal
Executive Officer) |
|
|
|
|
|
|
|
/s/
Jay Cross |
|
Chief
Financial Officer |
|
September
19, 2023 |
Jay
Cross |
|
(Principal
Financial and Accounting Officer) |
|
|
|
|
|
|
|
/s/
Nailesh Bhatt |
|
Director |
|
September
19, 2023 |
Nailesh
Bhatt |
|
|
|
|
|
|
|
|
|
/s/
Albert Dyrness |
|
Director |
|
September
19, 2023 |
Albert
Dyrness |
|
|
|
|
|
|
|
|
|
/s/
Donald Griffith |
|
Director |
|
September
19, 2023 |
Donald
Griffith |
|
|
|
|
|
|
|
|
|
/s/
Raghu Rao |
|
Director |
|
September
19, 2023 |
Raghu
Rao |
|
|
|
|
|
|
|
|
|
/s/
Lori McNeill |
|
Director |
|
September
19, 2023 |
Lori
McNeill |
|
|
|
|
EXHIBIT
INDEX
Exhibit
No. |
|
Description |
|
|
|
1.1* |
|
Form
of Underwriting Agreement |
|
|
|
2.1# |
|
Agreement and Plan of Merger, dated October 10, 2019, by and among the Company, Sonnet Sub. and Merger Sub (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K as filed on October 11, 2019, and incorporated herein by reference). |
|
|
|
2.2 |
|
Amendment No. 1 to Agreement and Plan of Merger, dated February 7, 2020, by and among the Company, Sonnet Sub and Merger Sub (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K as filed on February 7, 2020, and incorporated herein by reference). |
|
|
|
2.3# |
|
Share Exchange Agreement, between Sonnet BioTherapeutics, Inc. and Relief Therapeutics Holding SA, dated August 9, 2019 (incorporated by reference to Exhibit 2.10 to the Company’s Registration Statement on Form S-4 filed with the SEC on November 27, 2019). |
|
|
|
3.1 |
|
Certificate of Incorporation, as amended, of Sonnet BioTherapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2020). |
|
|
|
3.2 |
|
Amended and Restated Bylaws of Sonnet BioTherapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.3 to our Current Report on Form 8-K, filed with the SEC on August 15, 2022). |
|
|
|
4.1 |
|
Form of Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1 (Registration No. 333-178307), filed with the SEC on December 2, 2011). |
|
|
|
4.2 |
|
Form of Warrant dated May 4, 2017 (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K, filed with the SEC on May 5, 2017). |
|
|
|
4.3 |
|
Spin-Off Entity Warrant, dated April 1, 2020 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 3, 2020). |
|
|
|
4.4 |
|
Form of Sonnet BioTherapeutics, Inc. Converted Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2020). |
|
|
|
4.5 |
|
Form of Series A/B Warrants (incorporated by reference to Exhibit 4.16 to the Company’s Registration Statement on Form S-4/A filed with the SEC on February 7, 2020). |
|
|
|
4.6 |
|
Form of Series C Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on August 4, 2020). |
|
|
|
4.7 |
|
Registration Rights Agreement, dated February 7, 2020, by and between the Company and certain investors named therein (incorporated by reference to Exhibit 4.17 to the Company’s Registration Statement on Form S-4/A filed with the SEC on February 7, 2020). |
|
|
|
4.8 |
|
Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.8 to our Registration Statement on Form S-1 (Registration No. 333-269307), filed with the SEC on February 6, 2023). |
|
|
|
4.9 |
|
Form of Underwriter Warrant (Incorporated by reference to Exhibit 4.9 to our Registration Statement on Form S-1 (Registration No. 333-269307), filed with the SEC on February 6, 2023). |
|
|
|
4.10 |
|
Form of Common Warrant (Incorporated by reference to Exhibit 4.10 to our Registration Statement on Form S-1 (Registration No. 333-269307), filed with the SEC on February 6, 2023). |
|
|
|
4.11 |
|
Form of Pre-Funded Warrant dated June 30, 2023 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K, filed with the SEC on June 30, 2023). |
|
|
|
4.12 |
|
Form of Warrant dated June 30, 2023 (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K, filed with the SEC on June 30, 2023). |
4.13 |
|
Form of Placement Agent Warrant dated June 30, 2023 (incorporated by reference to Exhibit 4.3 to Current Report on Form 8-K, filed with the SEC on June 30, 2023). |
|
|
|
4.14* |
|
Form
of Pre-Funded Warrant. |
|
|
|
4.15* |
|
Form
of Underwriter Warrant. |
|
|
|
4.16* |
|
Form
of Common Warrant. |
|
|
|
5.1* |
|
Opinion
of Lowenstein Sandler LLP. |
|
|
|
10.1 |
|
Common Stock Purchase Agreement, between GEM Global Yield Fund LLC SCS and Sonnet BioTherapeutics, Inc., dated August 6, 2019 (incorporated by reference to Exhibit 10.54 to the Company’s Registration Statement on Form S-4 filed with the SEC on November 27, 2019). |
|
|
|
10.2 |
|
Amendment to Common Stock Purchase Agreement, between GEM Global Yield Fund LLC SCS and Sonnet BioTherapeutics, Inc., dated September 25, 2019 (incorporated by reference to Exhibit 10.55 to the Company’s Registration Statement on Form S-4 filed with the SEC on November 27, 2019). |
|
|
|
10.3 |
|
Side Letter and Amendment No. 2 to Common Stock Purchase Agreement, between GEM Global Yield Fund LLC SCS, Sonnet BioTherapeutics, Inc. and Chanticleer Holdings, Inc., dated February 7, 2020 (incorporated by reference to Exhibit 10.60 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). |
|
|
|
10.4 |
|
Employment Agreement, between Pankaj Mohan and Sonnet BioTherapeutics, Inc., dated December 31, 2018 (incorporated by reference to Exhibit 10.56 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). † |
|
|
|
10.5 |
|
Employment Agreement, between John Cini and Sonnet BioTherapeutics, Inc., dated January 10, 2020 (incorporated by reference to Exhibit 10.58 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). † |
|
|
|
10.6 |
|
Employment Agreement, between Jay Cross and Sonnet BioTherapeutics, Inc., dated January 10, 2020 (incorporated by reference to Exhibit 10.57 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). † |
|
|
|
10.7 |
|
Employment Agreement, between Susan Dexter and the Company, dated April 1, 2020 (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed with the SEC on April 3, 2020). † |
|
|
|
10.8 |
|
Offer Letter, between Donald Griffith and Sonnet BioTherapeutics, Inc., dated January 1, 2019 (incorporated by reference to Exhibit 10.59 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). † |
|
|
|
10.9 |
|
Sonnet BioTherapeutics Holdings, Inc. 2020 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-8 filed with the SEC on May 20, 2020). † |
|
|
|
10.10 |
|
Form of Restricted Stock Unit Award (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K (file No. 001-35570), filed with the SEC on July 9, 2020). † |
|
|
|
10.11*** |
|
License Agreement, between Ares Trading SA and Relief Therapeutics SA, dated August 28, 2015 (incorporated by reference to Exhibit 10.51 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). |
|
|
|
10.12*** |
|
Discovery Collaboration Agreement, between XOMA (US) LLC and Oncobiologics, Inc., dated July 23, 2012 (incorporated by reference to Exhibit 10.52 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). |
|
|
|
10.13*** |
|
Amendment of Discovery Collaboration Agreement, between XOMA (US) LLC and Sonnet BioTherapeutics, Inc., dated May 7, 2019 (incorporated by reference to Exhibit 10.53 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). |
10.14 |
|
Securities Purchase Agreement, dated as of February 7, 2020, by and among Chanticleer Holdings, Inc., Sonnet BioTherapeutics, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.64 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 7, 2020). |
|
|
|
10.15 |
|
Form of Warrant Exercise and Omnibus Amendment Agreement, dated as of August 3, 2020, by and between Sonnet BioTherapeutics Holdings, Inc. and the Holders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K (File No. 001-35570), filed with the SEC on August 4, 2020). |
|
|
|
10.16 |
|
Assignment and Assumption Employment Agreements by Sonnet BioTherapeutics Holdings, Inc., effective April 1, 2020 (incorporated by reference to Exhibit 10.16 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2020). |
|
|
|
10.17 |
|
Amendment No. 1 to Executive Employment Agreement, between Pankaj Mohan and the Company, dated November 23, 2020 (incorporated by reference to Exhibit 10.17 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2020). |
|
|
|
10.18 |
|
Amendment No. 1 to Executive Employment Agreement, between John Cini and the Company, dated November 23, 2020 (incorporated by reference to Exhibit 10.18 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2020). |
|
|
|
10.19 |
|
Form of Indemnification Agreement (incorporated by reference to Exhibit 10.19 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2020). |
|
|
|
10.20
|
|
At-The-Market Sales Agreement, dated February 5, 2020, between the Company and BTIG (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K (File No. 001-35570), filed with the SEC on February 5, 2021). |
|
|
|
10.21
|
|
License Agreement, dated May 2, 2021, between Sonnet BioTherapeutics, Inc. and New Life Therapeutics PTE, LTD (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q, filed with the SEC on May 17, 2021). |
|
|
|
10.22
|
|
First Amendment to License Agreement, dated June 11, 2021, between Sonnet BioTherapeutics, Inc. and New Life Therapeutics PTE, LTD (incorporated by reference to Exhibit 10.22 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2021). |
|
|
|
10.23
|
|
Second Amendment to License Agreement, dated July 7, 2021, among Sonnet Biotherapeutics CH SA, Sonnet BioTherapeutics, Inc. and New Life Therapeutics PTE, Ltd. (incorporated by reference to Exhibit 10.23 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2021). |
|
|
|
10.24
|
|
Amendment to License Agreement and Settlement, dated November 1, 2021, between ARES TRADING SA and Sonnet BioTherapeutics CH SA (incorporated by reference to Exhibit 10.24 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2021). |
|
|
|
10.25 |
|
At-The-Market Sales Agreement, dated August 15, 2022, between the Company and BTIG (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K, filed with the SEC on August 15, 2022). |
|
|
|
21.1 |
|
Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 to our Annual Report on Form 10-K, filed with the SEC on December 17, 2020). |
|
|
|
23.1** |
|
Consent of KPMG LLP |
|
|
|
23.2* |
|
Consent
of Lowenstein Sandler LLP (included as part of Exhibit 5.1). |
|
|
|
24.1** |
|
Power of attorney (included in the signature page to this registration statement) |
|
|
|
107** |
|
Filing Fee Table |
* |
To
be filed by amendment. |
** |
Filed
herewith. |
*** |
Filed
herewith; portions of the exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K. A copy of any omitted portions
will be furnished to the Securities and Exchange Commission upon request. |
# |
The
schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule
and/or exhibit will be furnished to the Securities and Exchange Commission upon request. |
Exhibit 23.1
Consent of Independent Registered Public Accounting
Firm
We consent to the use of our report dated December
15, 2022, with respect to the consolidated financial statements of Sonnet BioTherapeutics Holdings, Inc., incorporated herein by reference,
and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Philadelphia, Pennsylvania
September 19, 2023
Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
Sonnet BioTherapeutics Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
|
|
Security Type |
|
Security Class Title |
|
Fee Calculation or Carry Forward Rule |
|
|
Amount Registered |
|
|
Proposed Maximum Offering Price Per Share |
|
|
Maximum Aggregate Offering Price(1) |
|
|
Fee Rate |
|
|
Amount of Registration Fee |
|
Fees to Be
Paid |
|
Equity |
|
Common Stock, $0.0001 par value per share(2)(3) |
|
|
457 |
(o) |
|
|
|
|
|
|
|
|
|
$ |
10,000,000 |
|
|
|
0.0001102 |
|
|
|
1,102.00 |
|
Fees to Be
Paid |
|
Equity |
|
Pre-Funded Warrants(3) |
|
|
457 |
(g) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
Fees to Be
Paid |
|
Equity |
|
Common Warrants(3) |
|
|
457 |
(g) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
Fees to Be
Paid |
|
Equity |
|
Underwriter Warrants |
|
|
457 |
(g) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
Fees to Be
Paid |
|
Equity |
|
Common Stock underlying Pre-Funded Warrants(2)(3) |
|
|
457 |
(o) |
|
|
|
|
|
|
|
|
|
|
(3 |
) |
|
|
0.0001102 |
|
|
|
(3 |
) |
Fees to Be
Paid |
|
Equity |
|
Common Stock underlying Common Warrants(2) |
|
|
457 |
(o) |
|
|
|
|
|
|
|
|
|
$ |
10,000,000 |
|
|
|
0.0001102 |
|
|
|
1,102.00 |
|
Fees to Be
Paid |
|
Equity |
|
Common Stock underlying Underwriter Warrants(2) |
|
|
457 |
(o) |
|
|
|
|
|
|
|
|
|
$ |
875,000 |
|
|
|
0.0001102 |
|
|
|
96.43 |
|
|
|
|
|
Total Fees Previously Paid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
Total Fee Offsets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
— |
|
|
|
|
|
Net Fee Due |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
2,300.43 |
|
(1) |
Estimated solely for the purpose of calculating
the amount of the registration fee in pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). |
|
|
(2 |
Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover an indeterminate number of shares that may be issued and resold resulting from stock splits, stock dividends or similar transactions. |
|
|
(3) |
The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock, pre-funded warrants and accompanying common warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000. |
|
|
(4) |
No separate registration fee is payable
pursuant to Rule 457(g) under the Securities Act. |
Sonnet BioTherapeutics (NASDAQ:SONN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonnet BioTherapeutics (NASDAQ:SONN)
Historical Stock Chart
From Apr 2023 to Apr 2024